Rimtuzalcap (CAD-1883) (CAD-1883), a pioneering selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels), is employed in the study of movement disorders such as spinocerebellar ataxia (SCA) and essential tremor (ET).

Rimtuzalcap (Compound 1), a small-molecule modulator of potassium ion channels, exhibits significant therapeutic promise for addressing a range of diseases. These diseases are marked either by the dysfunction of potassium ion channels or by other factors affecting these channels[1].

Rimtuzalcap (CAD-1883) effectively decreases Purkinje cell firing rate by about 40%, aligning with its expected therapeutic action of enhancing SK channel activity through positive allosteric modulation. When applied in sequence, either 1 or 3 µM of CAD-1883 can partially reverse the augmented coefficient of variation in interspike intervals noted in cerebellar slices from 11-month-old spinocerebellar ataxia-2 58Q mice[1].